Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19.
Assay
COVID-19
Inflammation
MASP-2
Mannose-binding lectin-associated serine protease 2
Outcome
Journal
Journal of innate immunity
ISSN: 1662-8128
Titre abrégé: J Innate Immun
Pays: Switzerland
ID NLM: 101469471
Informations de publication
Date de publication:
11 Jul 2022
11 Jul 2022
Historique:
received:
04
03
2022
accepted:
05
06
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
aheadofprint
Résumé
Mannose-binding lectin-associated serine protease 2 (MASP-2) is the main activator of the lectin complement pathway and has been suggested to be involved in the pathophysiology of coronavirus disease 2019 (COVID-19). To study a possible association between MASP-2 and COVID-19, we aimed at developing a sensitive and reliable MASP-2 ELISA. From an array of novel mouse-monoclonal antibodies using recombinant MASP-2 as antigen, two clones were selected to create a sandwich ELISA. Plasma samples were obtained from 216 healthy controls, 347 convalescent COVID-19 patients, and 147 prospectively followed COVID-19 patients. The assay was specific towards MASP-2 and did not recognize the truncated MASP2 splice variant MAP-2 (MAp19). The limit of quantification was shown to be 0.1 ng/mL. MASP-2 concentration was found to be stable after multiple freeze-thaw cycles. In healthy controls, the mean MASP-2 concentration was 524 ng/mL (95% CI: 496.5-551.6). No significant difference was found in the MASP-2 concentrations between COVID-19 convalescent samples and controls. However, a significant increase was observed in prospectively followed COVID-19 patients (mean: 834 ng/mL [95% CI: 765.3-902.7, p < 0.0001]). In these patients, MASP-2 concentration correlated significantly with the concentrations of the terminal complement complex (ρ = 0.3596, p < 0.0001), with the lectin pathway pattern recognition molecules ficolin-2 (ρ = 0.2906, p = 0.0004) and ficolin-3 (ρ = 0.3952, p < 0.0001) and with C-reactive protein (ρ = 0.3292, p = 0.0002). Overall, we developed a specific quantitative MASP-2 sandwich ELISA. MASP-2 correlated with complement activation and inflammatory markers in COVID-19 patients, underscoring a possible role of MASP-2 in COVID-19 pathophysiology.
Identifiants
pubmed: 35816998
pii: 000525508
doi: 10.1159/000525508
pmc: PMC10643890
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Informations de copyright
© 2022 The Author(s). Published by S. Karger AG, Basel.
Références
J Immunol Methods. 2003 Nov;282(1-2):159-67
pubmed: 14604549
Clin Cancer Res. 2005 Feb 15;11(4):1441-6
pubmed: 15746044
Nat Commun. 2021 May 11;12(1):2697
pubmed: 33976229
Clin Exp Immunol. 2021 Jan;203(1):96-104
pubmed: 32681658
Mol Immunol. 2015 Sep;67(1):85-100
pubmed: 25862418
J Biol Chem. 2004 Jun 18;279(25):26058-65
pubmed: 15060079
Immunol Rev. 2016 Nov;274(1):74-97
pubmed: 27782323
Pathobiology. 2021;88(1):15-27
pubmed: 33049751
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Sci Rep. 2021 Oct 19;11(1):20638
pubmed: 34667241
Genes Immun. 2007 Mar;8(2):154-63
pubmed: 17252003
Eur J Immunol. 2021 Jul;51(7):1652-1659
pubmed: 33738806
Swiss Med Wkly. 2011 Apr 29;141:w13191
pubmed: 21528466
Viruses. 2021 Nov 26;13(12):
pubmed: 34960645
J Immunol Methods. 2011 Oct 28;373(1-2):89-101
pubmed: 21871896
J Immunol. 2000 Jul 15;165(2):878-87
pubmed: 10878362
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Scand J Immunol. 2004 Jan;59(1):97-102
pubmed: 14723627
J Immunol. 2013 Aug 1;191(3):1334-45
pubmed: 23785123
Front Microbiol. 2021 Nov 11;12:761887
pubmed: 34858373
Clin Exp Immunol. 2012 Jul;169(1):38-48
pubmed: 22670777
Front Immunol. 2020 Feb 21;11:201
pubmed: 32153567
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10498-503
pubmed: 22691502
Structure. 2015 Feb 3;23(2):342-51
pubmed: 25579818
Front Immunol. 2020 Oct 21;11:585243
pubmed: 33193407
PLoS One. 2013 Jul 30;8(7):e69054
pubmed: 23935922
Front Immunol. 2021 Jun 07;12:696085
pubmed: 34163491
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32554923
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Structure. 2017 Feb 7;25(2):364-375
pubmed: 28111019
BMC Nephrol. 2016 Oct 18;17(1):148
pubmed: 27760523
J Immunol. 2009 Mar 1;182(5):2939-47
pubmed: 19234189
J Thromb Haemost. 2016 Mar;14(3):531-45
pubmed: 26614707
Genet Mol Biol. 2021 Mar 17;44(1 Suppl 1):e20200199
pubmed: 33729332
Biochim Biophys Acta. 2012 Jan;1824(1):253-62
pubmed: 21664989
Immunol Rev. 2016 Nov;274(1):98-111
pubmed: 27782318
J Immunol. 2021 Jan 1;206(1):109-117
pubmed: 33208457
Clin Exp Immunol. 2013 Jul;173(1):112-20
pubmed: 23607747
Hybrid Hybridomics. 2003 Oct;22(5):321-7
pubmed: 14678650
Dan Med J. 2020 May 15;67(6):
pubmed: 32448405
Front Immunol. 2021 Jul 01;12:668725
pubmed: 34276659
Front Immunol. 2018 Sep 28;9:2238
pubmed: 30323815
Front Immunol. 2019 Mar 19;10:504
pubmed: 30941137
Int J Infect Dis. 2020 Jul;96:467-474
pubmed: 32425643
Immunology. 2010 Apr;129(4):482-95
pubmed: 20002787
Front Immunol. 2021 Jul 05;12:714511
pubmed: 34290717
PLoS One. 2014 Mar 14;9(3):e90979
pubmed: 24632598
PLoS One. 2007 Jul 18;2(7):e623
pubmed: 17637839
Genes Immun. 2001 May;2(3):119-27
pubmed: 11426320
Immunobiology. 2007;212(4-5):289-99
pubmed: 17544814
Kidney Int Rep. 2020 Aug 13;5(11):2032-2041
pubmed: 33163724
Front Immunol. 2021 Mar 25;12:663187
pubmed: 33841446
Scand J Immunol. 2007 Oct;66(4):458-64
pubmed: 17850591
Front Immunol. 2018 Nov 23;9:2742
pubmed: 30532757